Hot topic: JPM 2026 – It’s been a long time coming

/in

Every year the life science investment world looks forward to January’s ‘JPM week’, which revolves around the J.P. Morgan Annual Healthcare Conference in San Francisco. But this time there is real anticipation.  Because, after a number of times in which the event has promised to kick-start the investment market, only for the year to falter, this time expectations are much more solid.  Public biotech markets have been on a roll since April, with […]

Read more

Weekly roundup: Deals, discoveries, and market optimism

/in

Leucid Bio and Syenex announce strategic collaboration for in vivo CAR-T cell engineering Leucid Bio, a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, announced a strategic collaboration to access Syenex’s VivoCell Platform for the precise in vivo delivery of […]

Read more

Hot topic: FDA’s ‘plausible mechanism’ pathway could boost cell and gene therapies

/in

Good news for developers of drugs for ultra-rare diseases – including cell and gene therapy firms – in the form of a new way of assessing them that’s being proposed by the US’s Food and Drug Administration (FDA).  The regulator is looking at introducing what it calls a “plausible mechanism” pathway. This would allow approval of medicines for ultra-rare diseases, if there are very […]

Read more

Weekly roundup: Clinical breakthroughs, strategic appointments, and a dealmaker

/in

Oncoinvent published Phase 1 study results for Radspherin® in ovarian cancer in Gynecologic Oncology Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been […]

Read more

Hot topic: The race for the next obesity blockbuster

/in

As anyone who has been following the weight loss wars knows, today’s treatments are far from perfect.  They might be mega blockbusters, the likes of which have rarely been seen before in pharma, but that doesn’t mean they can’t be improved upon.  They have to be injected – weekly. They often cause nausea. And they […]

Read more